Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (FLGT) delivers innovative genetic testing and diagnostic solutions through its dual focus on clinical laboratory services and oncology therapeutic development. This news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, scientific advancements, and strategic initiatives.
Access authoritative reporting on earnings announcements, regulatory milestones, and partnership developments alongside analysis of FLGT’s expanding test menu and cancer research programs. Our curated news collection enables efficient tracking of operational updates across both laboratory services and drug development segments.
Key content includes coverage of diagnostic technology innovations, clinical trial progress, and healthcare collaborations that shape FLGT’s position in precision medicine. All materials are vetted for relevance to investment analysis and clinical practice trends.
Bookmark this page for streamlined access to Fulgent Genetics’ latest corporate developments, with new content added as official announcements are released through regulatory channels and company communications.
Fulgent Genetics has acquired CSI Laboratories to enhance its capabilities in somatic molecular diagnostics and cancer testing. CSI, known for its vast array of oncology tests, will complement Fulgent's expertise in next-generation sequencing (NGS). This acquisition aims to expand Fulgent’s market presence, with the somatic genetic testing market projected to reach $16.8 billion by 2030. Fulgent plans to leverage its technology platform and lab infrastructure to create a comprehensive cancer testing solution across the U.S., with a new lab in California enhancing operational capacity.
Fulgent Genetics (NASDAQ: FLGT) has partnered with Helio Health to commercialize blood-based early cancer detection tests. This partnership grants Fulgent exclusive rights for laboratory developed tests (LDTs) in the U.S. and Canada and includes a strategic investment in Helio. The focus will initially be on HelioLiver, a test for detecting liver cancer, which is currently in clinical trials. The companies aim to leverage their strengths in operations, marketing, and research to enhance early cancer detection capabilities and expand into additional tests for other cancers.
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q2 2021 financial results on August 5, 2021, after market close. Following this, a conference call will be hosted by CEO Ming Hsieh and other executives at 4:30 PM ET to discuss the results and answer questions. The company’s innovative technology platform offers extensive testing solutions, including full-gene sequencing and tailored options, ensuring high accuracy and competitive turnaround times, aimed to address diverse customer needs.
Fulgent Genetics (NASDAQ: FLGT) has announced a strategic investment of approximately $19 million in FF Gene Biotech, increasing its stake and control in the Chinese entity formed through a Joint Venture. This investment aims to enhance Fulgent's presence in China's rapidly growing genetic testing market, projected to reach $4.5 billion by 2030. The Joint Venture has generated over $10 million in revenue since inception, focusing on cancer, reproductive health, and pediatrics testing. This move is expected to positively impact Fulgent's consolidated financial results.
Fulgent Genetics (NASDAQ: FLGT) reported a remarkable first quarter for 2021, achieving a revenue of $359.4 million, representing an increase of 4,500% compared to $7.8 million in Q1 2020. The company recorded a GAAP income of $200.7 million or $6.52 per share. Expectations for Q2 are around $200 million in revenue, with a full-year forecast raised to $830 million, a 97% year-over-year growth. Significant contributions are anticipated from both RT-PCR and NGS testing, with GAAP income projected at $380 million for 2021.
Fulgent Genetics (NASDAQ: FLGT) will release its Q1 2021 financial results on May 6, 2021, after market close. A conference call for investors will follow at 4:30 PM ET, hosted by CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis. The call can be accessed via a live audio webcast or by dialing (800) 353-6461 with code 9490797. Fulgent’s advanced technology platform offers a wide array of genetic testing solutions, including RT-PCR tests for COVID-19, with Emergency Use Authorization from the FDA.
Fulgent Genetics has been awarded a contract by the CDC to conduct ongoing genomic sequencing of SARS-CoV-2 samples using its Next Generation Sequencing (NGS) capabilities. This partnership aims to facilitate a large-scale genomic survey of the virus, crucial for understanding transmission patterns and identifying emerging variants. The CDC's initiative is expected to enhance public health responses to COVID-19. Fulgent's expertise in COVID-19 testing solutions positions it as a key player in this critical research effort.
Fulgent Genetics (NASDAQ: FLGT) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. The company's executives, including Chairman and CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, will host a presentation at 8:40 a.m. ET.
A live webcast of the event will be accessible via the Investor Relations section of Fulgent Genetics' website.
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported record fourth quarter 2020 results with revenue of $295.0 million, a remarkable 3,400% increase year-over-year. The company achieved GAAP income of $166.3 million or $6.16 per share. Full-year revenue was $421.7 million, up 1,200% from 2019. Looking ahead to 2021, Fulgent anticipates overall revenue of approximately $800.0 million, reflecting a 90% growth. Non-COVID revenue grew 43% in Q4, and the company continues to expand its testing capabilities and customer base.
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
